Literature DB >> 17761114

Heart failure and cardiac hypertrophy.

J Eduardo Rame1, Daniel L Dries.   

Abstract

Left ventricular failure is the final common pathway for a wide spectrum of myocardial insults, including systemic hypertension and myocardial infarction. Although left ventricular hypertrophy is an adaptive response to pressure and volume overload, this process becomes maladaptive if left untreated and pathologic cardiac hypertrophy then becomes an important and independent risk factor for the development of heart failure. Despite its importance, the transition from hypertrophy to heart failure in humans is poorly understood. The focus of treatment should be prevention of heart failure and other cardiovascular events, such as stroke and atrial fibrillation. When heart failure is present, treatment with medical and device therapy is then focused on improving functional capacity, increasing survival, and preventing progression to end-stage heart failure.

Entities:  

Year:  2007        PMID: 17761114     DOI: 10.1007/s11936-007-0024-3

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  26 in total

1.  Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction.

Authors:  J Eduardo Rame; Marlon Ramilo; Nali Spencer; Christopher Blewett; Sameer K Mehta; Daniel L Dries; Mark H Drazner
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

Review 2.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Authors:  Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder
Journal:  Am J Med       Date:  2003-07       Impact factor: 4.965

3.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

4.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.

Authors:  Peter Carson; Barry M Massie; Robert McKelvie; John McMurray; Michel Komajda; Michael Zile; Agata Ptaszynska; Gerald Frangin
Journal:  J Card Fail       Date:  2005-10       Impact factor: 5.712

6.  Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

Authors:  Richard B Devereux; Björn Dahlöf; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine E Harris; Jonathan M Edelman; Kristian Wachtell
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

7.  Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment.

Authors:  M L Muiesan; M Salvetti; D Rizzoni; M Castellano; F Donato; E Agabiti-Rosei
Journal:  J Hypertens       Date:  1995-10       Impact factor: 4.844

8.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry.

Authors:  Marc Klapholz; Matthew Maurer; April M Lowe; Frank Messineo; Jay S Meisner; Judith Mitchell; Jill Kalman; Robert A Phillips; Richard Steingart; Edward J Brown; Robert Berkowitz; Robert Moskowitz; Anita Soni; Donna Mancini; Rachel Bijou; Khashayar Sehhat; Nikita Varshneya; Marrick Kukin; Stuart D Katz; Lynn A Sleeper; Thierry H Le Jemtel
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

10.  Recovery of insulin sensitivity in obese patients at short term after biliopancreatic diversion.

Authors:  Gian Franco Adami; Renzo Cordera; Giovanni Camerini; Giuseppe M Marinari; Nicola Scopinaro
Journal:  J Surg Res       Date:  2003-08       Impact factor: 2.192

View more
  8 in total

1.  Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes.

Authors:  Tao Tan; Peter M Scholz; Harvey R Weiss
Journal:  Life Sci       Date:  2010-05-12       Impact factor: 5.037

Review 2.  Cardiomyocyte autophagy: remodeling, repairing, and reconstructing the heart.

Authors:  Dian J Cao; Thomas G Gillette; Joseph A Hill
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

3.  Ectopic expression of S28A-mutated Histone H3 modulates longevity, stress resistance and cardiac function in Drosophila.

Authors:  J P Joos; A R Saadatmand; C Schnabel; I Viktorinová; T Brand; M Kramer; S Nattel; D Dobrev; P Tomancak; J Backs; P Kleinbongard; G Heusch; K Lorenz; E Koch; S Weber; A El-Armouche
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

4.  Amylin deposition activates HIF1α and 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) signaling in failing hearts of non-human primates.

Authors:  Miao Liu; Nan Li; Chun Qu; Yilin Gao; Lijie Wu; Liangbiao George Hu
Journal:  Commun Biol       Date:  2021-02-12

5.  Adult zebrafish hearts efficiently compensate for excessive forced overload cardiac stress with hyperplastic cardiomegaly.

Authors:  Maxime J Jean; Precious Deverteuil; Nicole H Lopez; Joshua D Tapia; Brenda Schoffstall
Journal:  Biores Open Access       Date:  2012-04

6.  The orphan receptor TR3 participates in angiotensin II-induced cardiac hypertrophy by controlling mTOR signalling.

Authors:  Rong-Hao Wang; Jian-Ping He; Mao-Long Su; Jie Luo; Ming Xu; Xiao-Dan Du; Hang-Zi Chen; Wei-Jia Wang; Yuan Wang; Nan Zhang; Bi-Xing Zhao; Wen-Xiu Zhao; Zhong-Gui Shan; Jiahuai Han; Chawnshang Chang; Qiao Wu
Journal:  EMBO Mol Med       Date:  2012-11-29       Impact factor: 12.137

7.  Phenanthrene exposure induces cardiac hypertrophy via reducing miR-133a expression by DNA methylation.

Authors:  Lixing Huang; Zhihui Xi; Chonggang Wang; Youyu Zhang; Zhibing Yang; Shiqi Zhang; Yixin Chen; Zhenghong Zuo
Journal:  Sci Rep       Date:  2016-02-01       Impact factor: 4.379

8.  Arginyltransferase knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 pathway.

Authors:  Kanika Singh; Ankit Gupta; Ashish Sarkar; Ishita Gupta; Santanu Rana; Sagartirtha Sarkar; Sameena Khan
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.